Overview

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare maintenance Aromatase Inhibitors (AIs) + everolimus with Aromatase Inhibitors alone after 1st line chemotherapy in patients with HR+ metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Collaborator:
University of Padova
Treatments:
Anastrozole
Aromatase Inhibitors
Everolimus
Exemestane
Hormones
Letrozole
Sirolimus